#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA1789905	F	NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.	Plasmodium yoelii	4,416		organism-based format	Novartis Malaria Screening
2.	ALA1040691	F	NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614		organism-based format	Novartis Malaria Screening
3.	ALA1040692	F	NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614		organism-based format	Novartis Malaria Screening
4.	ALA1040693	T	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	Homo sapiens	5,614		cell-based format	Novartis Malaria Screening
5.	ALA1040694	F	NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.		5,614		assay format	Novartis Malaria Screening
6.	ALA730079	F	ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye	Plasmodium falciparum	1,524		organism-based format	St Jude Malaria Screening
7.	ALA730080	F	ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye	Plasmodium falciparum	1,524		organism-based format	St Jude Malaria Screening
8.	ALA730081	F	ST_JUDE: Cytotoxicity against Plasmodium falciparum 3D7	Plasmodium falciparum	172		organism-based format	St Jude Malaria Screening
9.	ALA730641	F	ST_JUDE: Cytotoxicity against Plasmodium falciparum K1	Plasmodium falciparum	172		organism-based format	St Jude Malaria Screening
10.	ALA730642	F	ST_JUDE: Cytotoxicity against Plasmodium falciparum V1/S	Plasmodium falciparum	172		organism-based format	St Jude Malaria Screening
11.	ALA730643	F	ST_JUDE: Growth inhibition of to Toxoplasma gondii, in human U-2OS cells, as measured by luciferase.	Toxoplasma gondii	172		organism-based format	St Jude Malaria Screening
12.	ALA730920	F	ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of Trypanosoma brucei	Trypanosoma brucei	172		organism-based format	St Jude Malaria Screening
13.	ALA1038862	F	ST_JUDE: Cytotoxicity using Alamar Blue to measure viability of Leishmania major	Leishmania major	172		organism-based format	St Jude Malaria Screening
14.	ALA1038863	T	ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human foreskin fibroblast cells (BJ)	Homo sapiens	172		cell-based format	St Jude Malaria Screening
15.	ALA1038864	T	ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial hepatocellular carcinoma cells (HepG2)	Homo sapiens	172		cell-based format	St Jude Malaria Screening
16.	ALA1038865	T	ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial embryonic kidney cells (HEK293)	Homo sapiens	172		cell-based format	St Jude Malaria Screening
17.	ALA1038866	T	ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human Burkitt''s lymphoma lymphoblast cells (Raji)	Homo sapiens	172		cell-based format	St Jude Malaria Screening
18.	ALA1038867	F	ST_JUDE: Cytotoxicity against Plasmodium falciparum Dd2	Plasmodium falciparum	172		organism-based format	St Jude Malaria Screening
19.	ALA1038868	F	ST_JUDE: Cytotoxicity against Plasmodium falciparum W2	Plasmodium falciparum	172		organism-based format	St Jude Malaria Screening
20.	ALA1038869	F	ST_JUDE: Cytotoxicity against Plasmodium falciparum SB-A6	Plasmodium falciparum	172		organism-based format	St Jude Malaria Screening